5-氨基酮戊酸光动力疗法对尖锐湿疣皮损HPV6/11型DNA载量的影响及疗效观察

目的 分析研究5-氨基酮戊酸光动力疗法对尖锐湿疣(CA)皮损HPV6/11型DNA载量及疗效的影响。方法 此次研究对象均为尖锐湿疣患者,共计58例,纳入患者起始时间是2017年03月,截止时间是2019年04月,以随机数字表法实施分组,分别是对照组29例(予其电离子手术治疗)和治疗组29例(予其5-氨基酮戊酸光动力疗法治疗),比较两组总体治疗效果、HPV6/11型DNA载量、复发情况。结果 治疗组在治疗三个月后,其HPV6/11型DNA载量下降幅度较之对照组明显更加突出,差异比较存在显著性(P＜0.05);在治疗总有效率的比较上,治疗组显著高于对照组,有统计学意义(P＜0.05);在复发率的比较上,治疗组显著低于对照组,有统计学意义(P＜0.05)。结论 在治疗尖锐湿疣期间应用5-氨基酮戊酸光动力疗法,可促使HPV病毒载量显著降低,保证治疗效果实现最优化,避免病情的反复发作,具有推广价值。     

标题：雷贝拉唑10mg与20mg剂量预防胃食管反流病复发的meta分析

Background Several randomized controlled trials (RCTs) have compared endoscopic and symptomatic relapses in patients with erosive gastroesophageal reflux disease (GERD).We have summarized current evide...     

CD56抗原表达与急性早幼粒细胞白血病复发的关系

目的研究CD56抗原表达与急性早幼粒细胞白血病（AcutePromyelocyticLeukemia,APL）复发的相关性,为APL复发高危患者治疗提供参考。方法对100例确诊为APL的患者采用流式细胞术检测CD56的表达,均采用维甲酸联合蒽环类药物治疗,每3月进行骨髓检验,评价疾病缓解及复发情况。结果100例患者中CD56阳性表达27例,阴性表达73例;阳性组复发率为29．63％,高于阴性组的5．48％（P〈0．05）;阳性组外周白细胞计数水平高于阴性组（P〈0．01）;骨髓PML—RARA融合基因r型所占比例高于阴性组（P〈0．05）;阳性组正常核型所占比例低于阴性组（P〈0．05）。结论CD56抗原阳性表达的APL患者易复发,预后较差;CD56抗原可作为APL复发的预测指标。     

0.1%阿达帕林凝胶预防和减轻寻常痤疮复发的多中心随机对照临床试验

目的评价0.1%阿达帕林凝胶维持治疗对于预防和减轻寻常痤疮复发的作用.方法采用多中心、区组随机、开放、对照的方法,共入选患者246例,均为经过阿达帕林和克林霉素(特丽仙)联合治疗或特丽仙单独治疗获得有效(改善≥25%)的寻常痤疮患者,随机分为两组,一组外用0.1%阿达帕林凝胶,另一组不用药,均观察12周.结果239例患者完成治疗和观察,阿达帕林组121例,对照组118例.治疗4周后阿达帕林组炎性皮损数的减少显著优于对照组(P＜0.05),并维持至12周;治疗8周后阿达帕林组皮损总数和非炎性皮损数的减少也显著优于对照组(P＜0.01),并维持至12周.治疗结束后,阿达帕林组总体改善率为66.9%,对照组为4.2%(P＜0.01);阿达帕林组总复发率为4.1%,对照组为83.9%;两组间差异有显著性(P＜0.01).阿达帕林组有个别病例有轻度局部刺激反应,两组间不良反应差异无显著性(P＜0.05).结论阿达帕林凝胶可有效地治疗寻常痤疮,并维持治疗效果,且不增加局部刺激反应,对于减少病情复发具有显著效果.     

Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?

Positron emission tomography (PET) response assessment using the Deauville score has prognostic utility in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem-cell transplantation (ASCT). Improved predictive methods are required to identify patients with poor outcomes who may be better considered for other salvage options. We investigated the prognostic value of mean tumour volume (MTV) and maximum standardised uptake value (SUVmax) at pre-salvage and pre-ASCT time-points, and the quantitative changes between scans (∆MTV and ∆SUVmax). One hundred and twenty-five patients with R/R DLBCL underwent salvage immunochemotherapy and ASCT: 80 patients had pre-salvage PET and 90 had pre-ASCT PET available. With a median follow-up of 5.6 years, 5-year progression-free survival (PFS) and overall survival (OS) were 52% and 65%, respectively. For patients with PET-positive residual disease after salvage therapy, pre-ASCT MTV was a significant negative prognosticator for PFS (HR 1.19 per 100 ml, p < 0.001) and OS (HR 1.78 per 100 ml, p < 0.001). Similarly, pre-ASCT SUVmax was negatively associated with PFS (HR 1.08, p < 0.001) and OS (HR 1.08, p < 0.001). Notably, pre-salvage MTV and SUVmax and ∆MTV and ∆SUVmax were not associated with PFS or OS. In conclusion, pre-ASCT MTV and SUVmax appear to be of greater predictive value than the degree of response. Potential application may exist for PET-directed management of R/R DLBCL patients.     

伊曲康唑巩固疗法降低花斑癣复发率的临床研究

目的:探讨一种能够降低花斑癣复发率的有效治疗方案。方法:将初诊的花斑癣患者按就诊时间分为两组,均口服伊曲康唑0.2g,每日1次,连续服药7d。7d后对照组停药观察,试验组则继续服用伊曲康唑,每月口服0.2g1次,共6个月。两组患者皆每月复诊1次,共6次。结果:试验组99例患者复发率为1.01%,治愈率为85.86%。对照组95例患者复发率为17.89%,治愈率为64.21%。经卡方检验两组患者的复发率及治愈率相比,差异均有极显著性(χ2=16.4195,P=0.0001和χ2=12.2013,P=0.0005)。结论:巩固治疗方案能在近期内降低花斑癣复发率,同时提高花斑癣的治愈率。     

Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine

Aplastic anemia (AA) is an immune-mediated disease. Although most patients are responsive to immunosuppressive therapy (IST) with a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or are refractory to IST. Sirolimus (rapamysin) inhibits the serine-threonine kinase mammalian target of rapamysin (mTOR), and blocks CsA-resistant and calcium-independent pathways late in the progression of the T-cell cycle. We report two cases of AA which relapsed after CsA and ATG plus CsA, respectively. They achieved transfusion independence after retreatment with sirolimus in combination with a CsA.